Omega Therapeutics, a preclinical biotech developing gene therapies for oncology and other diseases, raised $126 million by offering 7.4 million shares at $17, within the range of $16 to $18.
Omega Therapeutics aims to use its proprietary OMEGA Epigenomic Programming platform to pioneer a new class of DNA-sequence-targeting, mRNA-encoded therapeutics. Its pipeline consists of preclinical programs that span regenerative medicine, multigenic diseases including immunology, oncology, and select monogenic diseases. The company has conducted in vivo preclinical studies in hepatocellular carcinoma, non-small cell lung cancer, and acute respiratory distress syndrome.
Omega Therapeutics plans to list on the Nasdaq under the symbol OMGA. Goldman Sachs, Jefferies, Piper Sandler, and Wedbush PacGrow acted as joint bookrunners on the deal.
